Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Pfizer

Status: Completed

Conditions: Plaque Psoriasis

Treatments: Drug: Enbrel

Study type: Observational

Funder types: Industry

Identifiers

NCT04398732

B1801412

Details and patient eligibility

About

This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e. age, gender, smoking status) using data from the Dermatologists in Baghdad Teaching Hospital registry

Enrollment: 486 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.
• Age ≥18 years old.
• No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.

Exclusion criteria

• Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration.
• Previous use of other biological treatments for any reason

Trial design

486 participants in 1 patient group

Patients with moderate to severe plaque psoriasis

Description:

Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.

Treatment:

Drug: Enbrel